RenovoRx, Inc. - Common Stock (RNXT)
1.0000
+0.0400 (4.17%)
NASDAQ · Last Trade: Apr 2nd, 9:03 PM EDT

Discover the top movers in Friday's pre-market session and stay informed about market dynamics.
Via Chartmill · February 7, 2025

Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session.
Via Chartmill · February 6, 2025

Via Benzinga · December 2, 2024

Via Benzinga · September 12, 2024

RNXT stock results show that RenovoRx met analyst estimates for earnings per share the second quarter of 2024.
Via InvestorPlace · August 13, 2024

RNXT stock results show that RenovoRx beat analyst estimates for earnings per share the first quarter of 2024.
Via InvestorPlace · May 13, 2024

Via Benzinga · June 14, 2024

Via Benzinga · June 12, 2024

Pre-market stock movers are worth checking out as we get into all of the hottest news investors need to know about on Tuesday morning!
Via InvestorPlace · April 9, 2024

RNXT stock results show that RenovoRx met analyst estimates for earnings per share the fourth quarter of 2023.
Via InvestorPlace · April 8, 2024

Via Benzinga · January 31, 2024

Via Benzinga · January 10, 2024

Via Benzinga · January 2, 2024

Via Benzinga · January 1, 2024

Shares of Longboard Pharmaceuticals, Inc.
Via Benzinga · January 2, 2024

Via Benzinga · December 29, 2023

Shares of DouYu International Holdings Limited (NASDAQ: DOYU) rose sharply during Thursday’s session after announcing a share repurchase program.
Via Benzinga · December 28, 2023
Biopharma Company Issues New Patent Application Adding to Strong IP Portfolio of 9 Patents Issued and 9 Pending; Phase 3 Clinical Trials for Cancer Treatments in Collaboration with Imugene: RenovoRx (NASDAQ: RNXT) $RNXT
Clinical-Stage Biopharma Company Developing Proprietary Targeted Combination Therapies for High Unmet Medical Needs in Oncology.
Via Viz Release · December 19, 2023

Via Benzinga · December 15, 2023

Via Benzinga · December 14, 2023

Via Benzinga · December 14, 2023

Via Benzinga · August 7, 2023
RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP™) Platform
--News Direct--
Via News Direct · July 20, 2023

RenovoRx, Inc. (NASDAQ: RNXT) shares are trading higher Thursday after the company released interim data on progression-free survival from Phase 3 open label TIGeR-PaC study of RenovoGem
Via Benzinga · June 29, 2023